Compugen (company)

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Retrieved on: 
Wednesday, November 1, 2023
Sale, PMM, Compugen (company), VTV (Belarusian TV channel), VTV, Therapy, Insulin, Pharmaceutical industry, T1D

“The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.

Key Points: 
  • “The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.
  • We remain in active discussions related to the financing, partnering and/or licensing of cadisegliatin,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
  • “We are excited about the therapeutic potential of mavodelpar and look forward to Reneo’s upcoming data readout.
  • Reneo’s lead program, mavodelpar, is a PPARδ agonist currently being studied in a pivotal Phase 2b clinical trial in adults with primary mitochondrial myopathies (PMM).

Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
Chemotherapy-induced peripheral neuropathy, Doctor of Health Science, Schizophrenia, Xavier University, MBA, Compugen (company), Nova Southeastern University, Drug development, CIPN, Doctorate, Outline of health sciences, BS, Biotechnology, Medicine, Hospital, Teva Pharmaceuticals, Cincinnati Children's Hospital Medical Center, AstraZeneca, Growth, Collection, Marketing, Trustee, Medical Center, Patient, Pharmaceutical industry, Medpace

Dr. Pearce led hundreds of global clinical trials at Medpace, where she later built out business development and marketing teams.

Key Points: 
  • Dr. Pearce led hundreds of global clinical trials at Medpace, where she later built out business development and marketing teams.
  • At Teva Pharmaceuticals, Dr. Pearce evaluated generics for repurposing, leading to the approval of Uzedy for the treatment of schizophrenia.
  • Catherine Pearce, DHSc, MBA, stated, "I am excited to be joining Bexion at this critical inflection point in their development of BXQ-350.
  • The health system, which licensed the technology to Bexion, stated: "Catherine is an accomplished biotech leader in both Cincinnati and the industry at large.

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

Retrieved on: 
Monday, October 2, 2023
Patent, Cancer, Compugen, Immunotherapy, Patient, TASE, TIGIT, PD-1, Pembrolizumab, Compugen (company), Pharmaceutical industry, PVRIG

HOLON, Israel, Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.

Key Points: 
  • HOLON, Israel, Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.
  • Japanese patent No.
  • JP7348072B2 , titled "Triple Combination Antibodies Therapies" augments previously issued patent in Japan by expanding and protecting Compugen's differentiated and leading triple blockade of the DNAM-1 axis with any anti-PVRIG in combination with any anti-TIGIT and anti-PD-1 antibody.
  • "We are delighted to strengthen our patent portfolio supporting our leadership in blocking three pathways of the DNAM-1 axis, PVRIG, TIGIT and PD-1", said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
Trident, National Science Advisory Board for Biosecurity, Catalyst Pharmaceuticals, State Government Affairs Council, Bristol Myers Squibb, Health policy, Trident University International, Government, Public health, Patient, Cypress, Alexion, Rare, CORAL, Alexion Pharmaceuticals, Compugen (company), Fine chemical, Management, Pharmaceutical industry, Science, Catalysis, D.C

CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023.

Key Points: 
  • CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023.
  • "I am honored to join the Catalyst Board at such a pivotal time in the Company’s history," said Ms. Thompson.
  • Ms. Thompson currently serves as Vice President, Head of Global Corporate Affairs for Alexion Pharmaceutical, AstraZeneca Rare Diseases.
  • Prior to joining Alexion, Ms. Thompson served as Executive Director, State Government Affairs and Federal Policy for Bristol-Myers Squibb Company.

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
Tuesday, May 30, 2023
Roswell Park Comprehensive Cancer Center, Focused Ultrasound Foundation, Partnership, Doctor of Pharmacy, University, CRC, Aster, American Society of Clinical Oncology, Cancer, Development of the human body, Research, Roswell Park, RNA, Immunotherapy, Doctor of Philosophy, AVATAR, ASCO, DO, Patient, Data, Sequence, Annual general meeting, Inherit, Genetic heterogeneity, Listeria monocytogenes non-coding RNA, H. Lee Moffitt Cancer Center & Research Institute, WES, Health, Society, Compugen (company), WTS, Pharmaceutical industry, Medical imaging, Vaccine

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Axys, Monoclonal antibody, US Foods, Interest, Crown Bioscience International, AbbVie, Quality of life, PDL, Rights, TKI, Research, NSCLC, Immunotherapy, Lung cancer, Forbes China Celebrity 100, Sale, Bayer Corporation, VEGF, Patient, Investment, EGFR, SMMT, Webcast, Knowledge, Entrepreneurship, PD-1, FDA, Woman, Summit, Collaboration, Phase, Compugen (company), Michelle, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Pfizer

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.
  • The Collaboration and License Agreement with Akeso closed on January 17, 2023 after going effective following customary waiting periods.
  • In exchange for these rights, Summit committed to an upfront payment of $500 million, which was paid in two installments.
  • Operating cash outflow for the three month ended March 31, 2023 and 2022 was $13.1 million and $19.0 million, respectively.

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

Retrieved on: 
Thursday, May 11, 2023
Drug discovery, United States Air Force Scientific Advisory Board, Compugen, Immunotherapy, Johns Hopkins University, TASE, TIGIT, PD-1, Research, Compugen (company), Pharmaceutical industry, PVRIG

HOLON, Israel, May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.

Key Points: 
  • HOLON, Israel, May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.
  • A short introductory presentation will be provided by Compugen's SVP Research and Drug Discovery, Eran Ophir, Ph.D., followed by a discussant presentation by Dr. Pardoll.
  • A live question and answer session with Dr. Pardoll and members of Compugen's leadership team will follow the formal presentations.
  • To register for the event, please click here .

Exscientia Business and Financial Update for the Full Year 2022

Retrieved on: 
Thursday, March 23, 2023
Technology, Research, Genetics, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Federal Reserve Bank, LSD1, AACR, Compugen (company), International, Inflammation, RCC, IGNITE, GMT, NGS, ESMO, Bone marrow, Pharmacokinetics, CDK7, G&A, Bristol Myers Squibb, Brain, NSCLC, Lung cancer, ID, EDT, Drug design, MALT1, Adenosine, ABS, Patient, Blood, Medicine, Sanofi, Growth, PD-1, Safety, Renal cell carcinoma, Pharmaceutical industry, Medical device, Cryptocurrency

Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.

Key Points: 
  • Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.
  • Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • Cash inflows: For the full year 2022, Exscientia received $117.8 million in cash inflows from its collaborations as compared to $85.3 million during the full year 2021.

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Retrieved on: 
Monday, March 20, 2023
Heart, North Point (Cambridge, Massachusetts), Interim, Partnership, Central nervous system, IPSC, Water Street, Immunity, Bristol Myers Squibb, Research, Immunotherapy, Messenger, CNS, Securities and Exchange Commission (Philippines), MD Anderson Cancer Center, Master service agreement, Patient, MSA, ERNA, Annual report, University, Growth, Security (finance), BMS, Letter, Therapy, IPS, Compugen (company), Pharmaceutical industry, Vaccine, Cryptocurrency, Eterna, Leukemia

CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced financial results for the quarter and year ended December 31, 2022 and provided a business update.

Key Points: 
  • In March and December 2022, Eterna announced the completion of two private placements yielding combined gross proceeds of approximately $20 million.
  • Research and development expenses were $2.0 million for the fourth quarter of 2022, which included $0.2 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $2.8 million for the fourth quarter of 2022, which included $0.2 million of non-cash stock-based compensation expense.
  • Earlier today, Eterna filed its Annual Report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Health, PD-1, Prostate cancer, Amgen, Research, Compugen (company), Sale, Patient, GSK, Rights, Collaboration, Stanford University School of Medicine, Senior, EPIX, MD, Webcast, Lung cancer, Interest, BTK, Entrepreneurship, Monoclonal antibody, US Foods, Hematological Cancer Research Investment and Education Act, VEGF, Executive, NSCLC, Immunotherapy, FDA, Panitumumab, Knowledge, R, Doctor of Philosophy, Colorectal cancer, SMMT, Celera Corporation, Crown Bioscience International, Biogen, Communication, Roche, Therapy, Quality of life, CMO, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Bayer, Pharmacyclics

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.
  • Summit is initiating development activities for SMT112 and will do so first in non-small cell lung cancer (NSCLC) indications.
  • Summit intends to start treating patients in clinical studies during the second quarter of 2023.
  • Summit’s management team will host an earnings call to discuss its fourth quarter 2022 financial results and provide an operational update for the Company today, March 9, 2023, at 9:00am ET.